Effect of alirocumab on cataracts in patients with acute coronary syndromes
Some data suggest that low levels of low-density lipoprotein cholesterol (LDL-C) are associated with risk of cataracts. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors reduce LDL-C below levels achieved with statins alone. We determined whether the incidence of cataracts was influen...
Saved in:
| Published in | BMC ophthalmology Vol. 23; no. 1; p. 279 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
16.06.2023
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Some data suggest that low levels of low-density lipoprotein cholesterol (LDL-C) are associated with risk of cataracts. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors reduce LDL-C below levels achieved with statins alone. We determined whether the incidence of cataracts was influenced by treatment with the PCSK9 inhibitor alirocumab versus placebo, and whether that incidence was affected by achieved LDL-C levels.
The ODYSSEY OUTCOMES trial (NCT01663402) compared alirocumab with placebo in 18,924 patients with recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin. Incident cataracts were pre-specified events of interest. In multivariable analysis using propensity score-matching on characteristics including cataract risk factors, incident cataracts were compared in the alirocumab and placebo groups according to LDL-C levels achieved with alirocumab.
Over median follow-up of 2.8 years (interquartile range 2.3 - 3.4), the incidence of cataracts was similar with alirocumab (127/9462 [1.3%]) versus placebo (134/9462 [1.4%]); hazard ratio [HR] 0.94, 95% confidence interval [CI] 0.74 - 1.20). In patients treated with alirocumab with ≥ 2 LDL-C values < 25 mg/dL (0.65 mmol/L), the incidence of cataracts was 71/4305 (1.6%), versus 60/4305 (1.4%) in propensity score-matched patients from the placebo group (HR 1.10, CI 95% 0.78 - 1.55). In patients treated with alirocumab with ≥ 2 LDL-C values < 15 mg/dL (0.39 mmol/L), the incidence of cataracts was 13/782 (1.7%), versus 36/2346 (1.5%) in matched patients from the placebo group (HR 1.03, CI 95% 0.54 - 1.94).
Treatment with alirocumab versus placebo, added to statin, did not influence the incidence of cataracts, even when achieved LDL-C levels on alirocumab were very low. Longer follow-up studies might be necessary to exclude the long-term effects on the incidence or progression of cataracts.
ClinicalTrials.gov Identifier: NCT01663402 . |
|---|---|
| AbstractList | Some data suggest that low levels of low-density lipoprotein cholesterol (LDL-C) are associated with risk of cataracts. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors reduce LDL-C below levels achieved with statins alone. We determined whether the incidence of cataracts was influenced by treatment with the PCSK9 inhibitor alirocumab versus placebo, and whether that incidence was affected by achieved LDL-C levels. The ODYSSEY OUTCOMES trial (NCT01663402) compared alirocumab with placebo in 18,924 patients with recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin. Incident cataracts were pre-specified events of interest. In multivariable analysis using propensity score-matching on characteristics including cataract risk factors, incident cataracts were compared in the alirocumab and placebo groups according to LDL-C levels achieved with alirocumab. Over median follow-up of 2.8 years (interquartile range 2.3 - 3.4), the incidence of cataracts was similar with alirocumab (127/9462 [1.3%]) versus placebo (134/9462 [1.4%]); hazard ratio [HR] 0.94, 95% confidence interval [CI] 0.74 - 1.20). In patients treated with alirocumab with [greater than or equal to] 2 LDL-C values < 25 mg/dL (0.65 mmol/L), the incidence of cataracts was 71/4305 (1.6%), versus 60/4305 (1.4%) in propensity score-matched patients from the placebo group (HR 1.10, CI 95% 0.78 - 1.55). In patients treated with alirocumab with [greater than or equal to] 2 LDL-C values < 15 mg/dL (0.39 mmol/L), the incidence of cataracts was 13/782 (1.7%), versus 36/2346 (1.5%) in matched patients from the placebo group (HR 1.03, CI 95% 0.54 - 1.94). Treatment with alirocumab versus placebo, added to statin, did not influence the incidence of cataracts, even when achieved LDL-C levels on alirocumab were very low. Longer follow-up studies might be necessary to exclude the long-term effects on the incidence or progression of cataracts. BackgroundSome data suggest that low levels of low-density lipoprotein cholesterol (LDL-C) are associated with risk of cataracts. Proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors reduce LDL-C below levels achieved with statins alone. We determined whether the incidence of cataracts was influenced by treatment with the PCSK9 inhibitor alirocumab versus placebo, and whether that incidence was affected by achieved LDL-C levels.MethodsThe ODYSSEY OUTCOMES trial (NCT01663402) compared alirocumab with placebo in 18,924 patients with recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin. Incident cataracts were pre-specified events of interest. In multivariable analysis using propensity score-matching on characteristics including cataract risk factors, incident cataracts were compared in the alirocumab and placebo groups according to LDL-C levels achieved with alirocumab.ResultsOver median follow-up of 2.8 years (interquartile range 2.3 − 3.4), the incidence of cataracts was similar with alirocumab (127/9462 [1.3%]) versus placebo (134/9462 [1.4%]); hazard ratio [HR] 0.94, 95% confidence interval [CI] 0.74 − 1.20). In patients treated with alirocumab with ≥ 2 LDL-C values < 25 mg/dL (0.65 mmol/L), the incidence of cataracts was 71/4305 (1.6%), versus 60/4305 (1.4%) in propensity score-matched patients from the placebo group (HR 1.10, CI 95% 0.78 − 1.55). In patients treated with alirocumab with ≥ 2 LDL-C values < 15 mg/dL (0.39 mmol/L), the incidence of cataracts was 13/782 (1.7%), versus 36/2346 (1.5%) in matched patients from the placebo group (HR 1.03, CI 95% 0.54 − 1.94).ConclusionTreatment with alirocumab versus placebo, added to statin, did not influence the incidence of cataracts, even when achieved LDL-C levels on alirocumab were very low. Longer follow-up studies might be necessary to exclude the long-term effects on the incidence or progression of cataracts.Trial registrationClinicalTrials.gov Identifier: NCT01663402. Abstract Background Some data suggest that low levels of low-density lipoprotein cholesterol (LDL-C) are associated with risk of cataracts. Proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors reduce LDL-C below levels achieved with statins alone. We determined whether the incidence of cataracts was influenced by treatment with the PCSK9 inhibitor alirocumab versus placebo, and whether that incidence was affected by achieved LDL-C levels. Methods The ODYSSEY OUTCOMES trial (NCT01663402) compared alirocumab with placebo in 18,924 patients with recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin. Incident cataracts were pre-specified events of interest. In multivariable analysis using propensity score-matching on characteristics including cataract risk factors, incident cataracts were compared in the alirocumab and placebo groups according to LDL-C levels achieved with alirocumab. Results Over median follow-up of 2.8 years (interquartile range 2.3 − 3.4), the incidence of cataracts was similar with alirocumab (127/9462 [1.3%]) versus placebo (134/9462 [1.4%]); hazard ratio [HR] 0.94, 95% confidence interval [CI] 0.74 − 1.20). In patients treated with alirocumab with ≥ 2 LDL-C values < 25 mg/dL (0.65 mmol/L), the incidence of cataracts was 71/4305 (1.6%), versus 60/4305 (1.4%) in propensity score-matched patients from the placebo group (HR 1.10, CI 95% 0.78 − 1.55). In patients treated with alirocumab with ≥ 2 LDL-C values < 15 mg/dL (0.39 mmol/L), the incidence of cataracts was 13/782 (1.7%), versus 36/2346 (1.5%) in matched patients from the placebo group (HR 1.03, CI 95% 0.54 − 1.94). Conclusion Treatment with alirocumab versus placebo, added to statin, did not influence the incidence of cataracts, even when achieved LDL-C levels on alirocumab were very low. Longer follow-up studies might be necessary to exclude the long-term effects on the incidence or progression of cataracts. Trial registration ClinicalTrials.gov Identifier: NCT01663402 . Some data suggest that low levels of low-density lipoprotein cholesterol (LDL-C) are associated with risk of cataracts. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors reduce LDL-C below levels achieved with statins alone. We determined whether the incidence of cataracts was influenced by treatment with the PCSK9 inhibitor alirocumab versus placebo, and whether that incidence was affected by achieved LDL-C levels. The ODYSSEY OUTCOMES trial (NCT01663402) compared alirocumab with placebo in 18,924 patients with recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin. Incident cataracts were pre-specified events of interest. In multivariable analysis using propensity score-matching on characteristics including cataract risk factors, incident cataracts were compared in the alirocumab and placebo groups according to LDL-C levels achieved with alirocumab. Over median follow-up of 2.8 years (interquartile range 2.3 - 3.4), the incidence of cataracts was similar with alirocumab (127/9462 [1.3%]) versus placebo (134/9462 [1.4%]); hazard ratio [HR] 0.94, 95% confidence interval [CI] 0.74 - 1.20). In patients treated with alirocumab with ≥ 2 LDL-C values < 25 mg/dL (0.65 mmol/L), the incidence of cataracts was 71/4305 (1.6%), versus 60/4305 (1.4%) in propensity score-matched patients from the placebo group (HR 1.10, CI 95% 0.78 - 1.55). In patients treated with alirocumab with ≥ 2 LDL-C values < 15 mg/dL (0.39 mmol/L), the incidence of cataracts was 13/782 (1.7%), versus 36/2346 (1.5%) in matched patients from the placebo group (HR 1.03, CI 95% 0.54 - 1.94). Treatment with alirocumab versus placebo, added to statin, did not influence the incidence of cataracts, even when achieved LDL-C levels on alirocumab were very low. Longer follow-up studies might be necessary to exclude the long-term effects on the incidence or progression of cataracts. ClinicalTrials.gov Identifier: NCT01663402 . Abstract Background Some data suggest that low levels of low-density lipoprotein cholesterol (LDL-C) are associated with risk of cataracts. Proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors reduce LDL-C below levels achieved with statins alone. We determined whether the incidence of cataracts was influenced by treatment with the PCSK9 inhibitor alirocumab versus placebo, and whether that incidence was affected by achieved LDL-C levels. Methods The ODYSSEY OUTCOMES trial (NCT01663402) compared alirocumab with placebo in 18,924 patients with recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin. Incident cataracts were pre-specified events of interest. In multivariable analysis using propensity score-matching on characteristics including cataract risk factors, incident cataracts were compared in the alirocumab and placebo groups according to LDL-C levels achieved with alirocumab. Results Over median follow-up of 2.8 years (interquartile range 2.3 − 3.4), the incidence of cataracts was similar with alirocumab (127/9462 [1.3%]) versus placebo (134/9462 [1.4%]); hazard ratio [HR] 0.94, 95% confidence interval [CI] 0.74 − 1.20). In patients treated with alirocumab with ≥ 2 LDL-C values < 25 mg/dL (0.65 mmol/L), the incidence of cataracts was 71/4305 (1.6%), versus 60/4305 (1.4%) in propensity score-matched patients from the placebo group (HR 1.10, CI 95% 0.78 − 1.55). In patients treated with alirocumab with ≥ 2 LDL-C values < 15 mg/dL (0.39 mmol/L), the incidence of cataracts was 13/782 (1.7%), versus 36/2346 (1.5%) in matched patients from the placebo group (HR 1.03, CI 95% 0.54 − 1.94). Conclusion Treatment with alirocumab versus placebo, added to statin, did not influence the incidence of cataracts, even when achieved LDL-C levels on alirocumab were very low. Longer follow-up studies might be necessary to exclude the long-term effects on the incidence or progression of cataracts. Trial registration ClinicalTrials.gov Identifier: NCT01663402 . BACKGROUNDSome data suggest that low levels of low-density lipoprotein cholesterol (LDL-C) are associated with risk of cataracts. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors reduce LDL-C below levels achieved with statins alone. We determined whether the incidence of cataracts was influenced by treatment with the PCSK9 inhibitor alirocumab versus placebo, and whether that incidence was affected by achieved LDL-C levels. METHODSThe ODYSSEY OUTCOMES trial (NCT01663402) compared alirocumab with placebo in 18,924 patients with recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin. Incident cataracts were pre-specified events of interest. In multivariable analysis using propensity score-matching on characteristics including cataract risk factors, incident cataracts were compared in the alirocumab and placebo groups according to LDL-C levels achieved with alirocumab. RESULTSOver median follow-up of 2.8 years (interquartile range 2.3 - 3.4), the incidence of cataracts was similar with alirocumab (127/9462 [1.3%]) versus placebo (134/9462 [1.4%]); hazard ratio [HR] 0.94, 95% confidence interval [CI] 0.74 - 1.20). In patients treated with alirocumab with ≥ 2 LDL-C values < 25 mg/dL (0.65 mmol/L), the incidence of cataracts was 71/4305 (1.6%), versus 60/4305 (1.4%) in propensity score-matched patients from the placebo group (HR 1.10, CI 95% 0.78 - 1.55). In patients treated with alirocumab with ≥ 2 LDL-C values < 15 mg/dL (0.39 mmol/L), the incidence of cataracts was 13/782 (1.7%), versus 36/2346 (1.5%) in matched patients from the placebo group (HR 1.03, CI 95% 0.54 - 1.94). CONCLUSIONTreatment with alirocumab versus placebo, added to statin, did not influence the incidence of cataracts, even when achieved LDL-C levels on alirocumab were very low. Longer follow-up studies might be necessary to exclude the long-term effects on the incidence or progression of cataracts. TRIAL REGISTRATIONClinicalTrials.gov Identifier: NCT01663402 . Background Some data suggest that low levels of low-density lipoprotein cholesterol (LDL-C) are associated with risk of cataracts. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors reduce LDL-C below levels achieved with statins alone. We determined whether the incidence of cataracts was influenced by treatment with the PCSK9 inhibitor alirocumab versus placebo, and whether that incidence was affected by achieved LDL-C levels. Methods The ODYSSEY OUTCOMES trial (NCT01663402) compared alirocumab with placebo in 18,924 patients with recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin. Incident cataracts were pre-specified events of interest. In multivariable analysis using propensity score-matching on characteristics including cataract risk factors, incident cataracts were compared in the alirocumab and placebo groups according to LDL-C levels achieved with alirocumab. Results Over median follow-up of 2.8 years (interquartile range 2.3 - 3.4), the incidence of cataracts was similar with alirocumab (127/9462 [1.3%]) versus placebo (134/9462 [1.4%]); hazard ratio [HR] 0.94, 95% confidence interval [CI] 0.74 - 1.20). In patients treated with alirocumab with [greater than or equal to] 2 LDL-C values < 25 mg/dL (0.65 mmol/L), the incidence of cataracts was 71/4305 (1.6%), versus 60/4305 (1.4%) in propensity score-matched patients from the placebo group (HR 1.10, CI 95% 0.78 - 1.55). In patients treated with alirocumab with [greater than or equal to] 2 LDL-C values < 15 mg/dL (0.39 mmol/L), the incidence of cataracts was 13/782 (1.7%), versus 36/2346 (1.5%) in matched patients from the placebo group (HR 1.03, CI 95% 0.54 - 1.94). Conclusion Treatment with alirocumab versus placebo, added to statin, did not influence the incidence of cataracts, even when achieved LDL-C levels on alirocumab were very low. Longer follow-up studies might be necessary to exclude the long-term effects on the incidence or progression of cataracts. Trial registration ClinicalTrials.gov Identifier: NCT01663402. Keywords: Acute coronary syndrome, Cataracts, Alirocumab, PCSK9 inhibitor |
| ArticleNumber | 279 |
| Audience | Academic |
| Author | Suc, Gaspard Jukema, J Wouter Manvelian, Garen Pordy, Robert Goodman, Shaun G Scemama, Michel Schwartz, Gregory G Poulouin, Yann Szarek, Michael Steg, Ph Gabriel |
| Author_xml | – sequence: 1 givenname: Gaspard surname: Suc fullname: Suc, Gaspard organization: Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France – sequence: 2 givenname: Gregory G surname: Schwartz fullname: Schwartz, Gregory G organization: Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA – sequence: 3 givenname: Shaun G surname: Goodman fullname: Goodman, Shaun G organization: St. Michael's Hospital, University of Toronto, Toronto, ON, Canada – sequence: 4 givenname: J Wouter surname: Jukema fullname: Jukema, J Wouter organization: Netherlands Heart Institute, Utrecht, the Netherlands – sequence: 5 givenname: Garen surname: Manvelian fullname: Manvelian, Garen organization: Regeneron Pharmaceuticals, Tarrytown, NY, USA – sequence: 6 givenname: Yann surname: Poulouin fullname: Poulouin, Yann organization: IT&M Stats, Neuilly-sur-Seine, France – sequence: 7 givenname: Robert surname: Pordy fullname: Pordy, Robert organization: Regeneron Pharmaceuticals, Tarrytown, NY, USA – sequence: 8 givenname: Michel surname: Scemama fullname: Scemama, Michel organization: Sanofi, Chilly-Mazarin, France – sequence: 9 givenname: Michael surname: Szarek fullname: Szarek, Michael organization: CPC Clinical Research and Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA – sequence: 10 givenname: Ph Gabriel surname: Steg fullname: Steg, Ph Gabriel email: gabriel.steg@aphp.fr, gabriel.steg@aphp.fr, gabriel.steg@aphp.fr, gabriel.steg@aphp.fr, gabriel.steg@aphp.fr organization: Département de Cardiologie, AP-HP Hôpital Bichat, 46 Rue Henri Huchard, Paris, 75018, France. gabriel.steg@aphp.fr |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37328736$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkktv1DAUhS1URB_wB1igSGzYpPiV2FmhqipQtRIbWFvXr6lHiT3YCaj_Hs9MKZ0KeWHr-tzPPlfnFB3FFB1Cbwk-J0T2HwuhUvYtpqzFDBPakhfohHBBWspJd_TkfIxOS1ljTDFn8hU6ZoJRKVh_gm6uvHdmbpJvYAw5mWUC3aTYGJghg5lLE2KzgTm4WM-_w3zXgFlm15iUU4R835T7aHOaXHmNXnoYi3vzsJ-hH5-vvl9-bW-_fbm-vLhtTdfzuZVU6w4bg6X1wD2QjmNNLBmYIUZ7zZm1g6PUY4s73QvdCSDOYKqtAOkkO0PXe65NsFabHKb6DZUgqF0h5ZWCPAczOlXHAqLnwHvmuAE22F5jLJhzFFg3sMr6tGdtFj05a6rLDOMB9PAmhju1Sr8UwbSCCa-EDw-EnH4ursxqCsW4cYTo0lIUlVTQTko8VOn7Z9J1WnKss9qpcMep5P9UK6gOQvSpPmy2UHUhOkb7aoBU1fl_VHVZNwVTg-JDrR800H2DyamU7PyjSYLVNk9qnydV86R2eVLbpndPx_PY8jdA7A-gksZy |
| CitedBy_id | crossref_primary_10_1093_ehjcvp_pvae025 crossref_primary_10_1186_s12886_023_03065_2 |
| Cites_doi | 10.1056/NEJMoa1801174 10.1056/NEJMoa1600176 10.1016/j.jacc.2005.04.064 10.1161/CIRCULATIONAHA.122.063399 10.3109/02713688409007421 10.1093/eurheartj/ehy182 10.1093/ehjcvp/pvac049 10.1161/JAHA.116.004180 10.1016/j.jacl.2018.02.002 10.1016/S2213-8587(19)30158-5 10.1136/heartjnl-2021-320556 10.1016/j.jacc.2016.11.037 10.1016/j.ahj.2014.07.028 10.1016/S0039-6257(96)82007-8 10.1001/jama.1987.03390120064020 10.1016/j.amjcard.2014.08.041 10.1001/jamacardio.2017.0083 10.1093/eurheartj/ehaa1080 10.1016/j.jacc.2018.04.054 10.1016/S0140-6736(17)30544-5 10.1016/j.jacc.2016.10.060 |
| ContentType | Journal Article |
| Copyright | 2023. The Author(s). COPYRIGHT 2023 BioMed Central Ltd. 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2023 |
| Copyright_xml | – notice: 2023. The Author(s). – notice: COPYRIGHT 2023 BioMed Central Ltd. – notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2023 |
| CorporateAuthor | ODYSSEY OUTCOMES Investigators |
| CorporateAuthor_xml | – name: ODYSSEY OUTCOMES Investigators |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7TK 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12886-023-03012-1 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database CrossRef MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2415 |
| EndPage | 279 |
| ExternalDocumentID | oai_doaj_org_article_301a764a463e4ca39d6b0073ee2a3593 A753260071 10_1186_s12886_023_03012_1 37328736 |
| Genre | Journal Article |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GrantInformation_xml | – fundername: ; |
| GroupedDBID | --- -A0 0R~ 23N 2WC 3V. 53G 5GY 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABUWG ACGFO ACGFS ACIHN ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EBD EBLON EBS ECM EIF EMB EMOBN F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 UKHRP W2D WOQ WOW XSB AAYXX CITATION ABVAZ AFGXO AFNRJ 7TK 7XB 8FK AZQEC DWQXO K9. PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c564t-82bb50cc08dfa4fa1540b1d193c1cbfb43dd9e22f0d05b67b57a1ec02bd7a8e83 |
| IEDL.DBID | RPM |
| ISSN | 1471-2415 |
| IngestDate | Fri Oct 04 12:57:40 EDT 2024 Tue Sep 17 21:29:59 EDT 2024 Fri Aug 16 06:28:02 EDT 2024 Fri Sep 13 05:03:27 EDT 2024 Thu Feb 22 23:54:09 EST 2024 Fri Feb 02 04:19:16 EST 2024 Thu Sep 12 20:17:19 EDT 2024 Sat Sep 28 08:11:18 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Cataracts PCSK9 inhibitor Alirocumab Acute coronary syndrome |
| Language | English |
| License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c564t-82bb50cc08dfa4fa1540b1d193c1cbfb43dd9e22f0d05b67b57a1ec02bd7a8e83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276414/ |
| PMID | 37328736 |
| PQID | 2827054284 |
| PQPubID | 44797 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_301a764a463e4ca39d6b0073ee2a3593 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10276414 proquest_miscellaneous_2827258809 proquest_journals_2827054284 gale_infotracmisc_A753260071 gale_infotracacademiconefile_A753260071 crossref_primary_10_1186_s12886_023_03012_1 pubmed_primary_37328736 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-06-16 |
| PublicationDateYYYYMMDD | 2023-06-16 |
| PublicationDate_xml | – month: 06 year: 2023 text: 2023-06-16 day: 16 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC ophthalmology |
| PublicationTitleAlternate | BMC Ophthalmol |
| PublicationYear | 2023 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | 37415129 - BMC Ophthalmol. 2023 Jul 6;23(1):301 JM Dobrzynski (3012_CR9) 2018; 12 J Li (3012_CR10) 2022; 108 MC Elze (3012_CR23) 2017; 69 BM Everett (3012_CR21) 2014; 114 F Mach (3012_CR6) 2018; 39 3012_CR11 AD Karagiannis (3012_CR5) 2021; 42 G Patti (3012_CR12) 2023; 9 GG Schwartz (3012_CR17) 2018; 379 KK Ray (3012_CR13) 2019; 7 RJ Cenedella (3012_CR3) 1987; 257 RS Rosenson (3012_CR8) 2018; 72 SD Wiviott (3012_CR22) 2005; 46 PS Zelenka (3012_CR2) 1984; 3 YC Liu (3012_CR1) 2017; 390 GG Schwartz (3012_CR16) 2014; 168 S Yu (3012_CR15) 2017; 6 AJ Bentz (3012_CR7) 2018; 35 RP Giugliano (3012_CR20) 2017; 2 P Zakrzewski (3012_CR18) 2002; 57 JG Robinson (3012_CR14) 2017; 69 RJ Cenedella (3012_CR4) 1996; 40 S Yusuf (3012_CR19) 2016; 374 |
| References_xml | – volume: 379 start-page: 2097 issue: 22 year: 2018 ident: 3012_CR17 publication-title: N Engl J Med doi: 10.1056/NEJMoa1801174 contributor: fullname: GG Schwartz – volume: 374 start-page: 2021 issue: 21 year: 2016 ident: 3012_CR19 publication-title: N Engl J Med doi: 10.1056/NEJMoa1600176 contributor: fullname: S Yusuf – volume: 46 start-page: 1411 issue: 8 year: 2005 ident: 3012_CR22 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2005.04.064 contributor: fullname: SD Wiviott – ident: 3012_CR11 doi: 10.1161/CIRCULATIONAHA.122.063399 – volume: 3 start-page: 1337 issue: 11 year: 1984 ident: 3012_CR2 publication-title: Curr Eye Res doi: 10.3109/02713688409007421 contributor: fullname: PS Zelenka – volume: 39 start-page: 2526 issue: 27 year: 2018 ident: 3012_CR6 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehy182 contributor: fullname: F Mach – volume: 9 start-page: 138 issue: 2 year: 2023 ident: 3012_CR12 publication-title: Eur Heart J Cardiovasc Pharmacother doi: 10.1093/ehjcvp/pvac049 contributor: fullname: G Patti – volume: 6 start-page: e004180 issue: 3 year: 2017 ident: 3012_CR15 publication-title: J Am Heart Assoc doi: 10.1161/JAHA.116.004180 contributor: fullname: S Yu – volume: 35 start-page: 26 issue: 10 year: 2018 ident: 3012_CR7 publication-title: Fed Pract contributor: fullname: AJ Bentz – volume: 12 start-page: 728 issue: 3 year: 2018 ident: 3012_CR9 publication-title: J Clin Lipidol doi: 10.1016/j.jacl.2018.02.002 contributor: fullname: JM Dobrzynski – volume: 7 start-page: 618 issue: 8 year: 2019 ident: 3012_CR13 publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(19)30158-5 contributor: fullname: KK Ray – volume: 108 start-page: 1296 issue: 16 year: 2022 ident: 3012_CR10 publication-title: Heart doi: 10.1136/heartjnl-2021-320556 contributor: fullname: J Li – volume: 69 start-page: 471 issue: 5 year: 2017 ident: 3012_CR14 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2016.11.037 contributor: fullname: JG Robinson – volume: 168 start-page: 682 issue: 5 year: 2014 ident: 3012_CR16 publication-title: Am Heart J doi: 10.1016/j.ahj.2014.07.028 contributor: fullname: GG Schwartz – volume: 40 start-page: 320 issue: 4 year: 1996 ident: 3012_CR4 publication-title: Surv Ophthalmol doi: 10.1016/S0039-6257(96)82007-8 contributor: fullname: RJ Cenedella – volume: 57 start-page: 165 issue: 2 year: 2002 ident: 3012_CR18 publication-title: Ann Univ Mariae Curie Sklodowska Med contributor: fullname: P Zakrzewski – volume: 257 start-page: 1602 issue: 12 year: 1987 ident: 3012_CR3 publication-title: JAMA doi: 10.1001/jama.1987.03390120064020 contributor: fullname: RJ Cenedella – volume: 114 start-page: 1682 issue: 11 year: 2014 ident: 3012_CR21 publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2014.08.041 contributor: fullname: BM Everett – volume: 2 start-page: 547 issue: 5 year: 2017 ident: 3012_CR20 publication-title: JAMA Cardiol doi: 10.1001/jamacardio.2017.0083 contributor: fullname: RP Giugliano – volume: 42 start-page: 2154 issue: 22 year: 2021 ident: 3012_CR5 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehaa1080 contributor: fullname: AD Karagiannis – volume: 72 start-page: 314 issue: 3 year: 2018 ident: 3012_CR8 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2018.04.054 contributor: fullname: RS Rosenson – volume: 390 start-page: 600 issue: 10094 year: 2017 ident: 3012_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(17)30544-5 contributor: fullname: YC Liu – volume: 69 start-page: 345 issue: 3 year: 2017 ident: 3012_CR23 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2016.10.060 contributor: fullname: MC Elze |
| SSID | ssj0020438 |
| Score | 2.3620288 |
| Snippet | Some data suggest that low levels of low-density lipoprotein cholesterol (LDL-C) are associated with risk of cataracts. Proprotein convertase subtilisin-kexin... Abstract Background Some data suggest that low levels of low-density lipoprotein cholesterol (LDL-C) are associated with risk of cataracts. Proprotein... Background Some data suggest that low levels of low-density lipoprotein cholesterol (LDL-C) are associated with risk of cataracts. Proprotein convertase... BackgroundSome data suggest that low levels of low-density lipoprotein cholesterol (LDL-C) are associated with risk of cataracts. Proprotein convertase... BACKGROUNDSome data suggest that low levels of low-density lipoprotein cholesterol (LDL-C) are associated with risk of cataracts. Proprotein convertase... Abstract Background Some data suggest that low levels of low-density lipoprotein cholesterol (LDL-C) are associated with risk of cataracts. Proprotein... |
| SourceID | doaj pubmedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 279 |
| SubjectTerms | Acute coronary syndrome Acute Coronary Syndrome - drug therapy Acute coronary syndromes Age Alirocumab Apolipoproteins Body mass index Cardiac patients Cardiovascular agents Care and treatment Cataract Cataract - chemically induced Cataract - drug therapy Cataract - epidemiology Cataracts Cholesterol Cholesterol, LDL - therapeutic use Clinical trials Comparative analysis Coronary heart disease Diabetes Double-Blind Method Drug dosages Hemoglobin Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Kexin Lipoproteins Long-term effects Low density lipoprotein Low density lipoproteins Monoclonal antibodies Ophthalmology Patients PCSK9 inhibitor Placebos Proprotein Convertase 9 - therapeutic use Proprotein convertases Risk factors Statins Statistical analysis Subtilisin Treatment Outcome Visual impairment |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV29b9UwELdQB8SCKJ8pBRkJiQFZdfydsUVUFahMVOpm2Y4tOpCHmvcG_nvu4uTpRQwsrPFFiX939t3Z558JeZ-0sdymwoI2HVMuGhZkUcxGKXhXdIoRDydffzNXN-rLrb49uOoLa8IqPXAF7gwMMFijgjIyqxRk15uI20s5iyB1V3k-W70kU3OqhftbyxEZZ85GmIUdFttKhimAYO3KDU1s_X_PyQdOaV0weeCBLp-Qx3PoSM_rLx-TB3l4Sh5ez5vjz8jXykRMN4VCcA2OafczRLoZKC7R4GGokd4NdCZSHSmuwNKQdttME9IYhPvfdOEvGJ-Tm8vP3z9dsfmuBAZoqy1zIkbNU-KuL0GVAJERj20P4VlqUyxRyb7vshCF91xHY6O2oc2Ji9jb4LKTL8jRsBnyK0KjSalkRN1xlXjvuAG1iZBdLtl1bUM-LtD5X5USw0-phDO-Au0BaD8B7UH6AtHdSyKd9fQAlOxnJft_KbkhH1A3HgcdKCCF-ewA_DDSV_lzSLompn343OlKEgZLWjcv2vXzYB09ZJ0WIldw1A15t2_GN7EAbcibXZURGia7riEvqzHsuySR8MhK0xC3MpNVn9ctw92Picobwjvod6tO_gdKr8kjMZm4Ya05JUfb-11-AyHTNr6dRscfVI4SVg priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZKkRAXRHkGSmUkJA7IWsd2HOeECmq1KionKu3Nsh0bemhSNtkD_56ZPLaNkLjGE9kez4znYX8m5EModMnLkJgrdMWU8Zo5mRQrvRS8SkXwHi8nX37X6yt1sSk2B2Q934XBY5WzTRwMdd0GzJGvIDQowb0Aa7pyHrMAoV99vv3N8P0orLNOj2k8IA9zAW4FSHa5uQu9sN41X5kxetWBVTZ4-FYyDAkEyxfb0oDe_6-NvrdJLQ9Q3tuRzp-SJ5MrSU_HtT8iB7F5Rh5dTsXy5-TbiExM20TB2YaNanfjPG0biikbnFlHrxs6Aat2FDOy1IVdH2lAWAO3_UNnPIPuBbk6P_vxdc2mtxMYcF_1zAjvCx4CN3VyKjnwlLjPa3DXQh588krWdRWFSLzmhdelL0qXx8CFr0tnopEvyWHTNvE1oV6HkGLuIDDhKvDacA3LKFw0MUVT5Rn5NLPO3o4QGXYILYy2I6MtMNoOjLZA_QW5u6dEeOvhQ7v9aSdtsUAK3SmntIwqOFnV2mNNMUbhZFHJjHzEtbGohCgKbrpLAANGOCt7CkHYgLwP3R0vKEF5wrJ5Xl07KW9n70QtI-_3zfgnHkhrYrsbaUQBxq_KyKtRGPZTkgiAVEqdEbMQk8Wcly3N9a8B2hvcPZh3rt78f1xvyWMxCK9muT4mh_12F9-Bc9T7k0Hu_wJKhw5S priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3Ni9UwEA_LCuJF_La6SgTBg0TTJE3Tg8gqLovyPPlgbyFJE11YW319D9z_3pm0fWxxD16badPMR2YmyfxCyMtQ6ZrXITFX6YYp4zVzMilWeyl4k6rgPRYnr77q07X6fFadHZD5uqOJgcO1qR3eJ7XeXLz58_vyPRj8u2zwRr8dYI41eJRWMgzwBYNs6IZQUqHGr9R-VwHLQHNpHEzIDD3XXERz7TcWjirj-f87a19xW8sjlVd81MkdcnsKLunxqA13yUHs7pGbq2n7_D75MmIV0z5RCL_Bde1-Ok_7juIiDpZLDfS8oxPU6kBxjZa6sNtGGhDowG0u6YxwMDwg65NP3z6esuk2BQbyUFtmhPcVD4GbNjmVHMRO3JctBHChDD55Jdu2iUIk3vLK69pXtStj4MK3tTPRyIfksOu7-JhQr0NIsXSQqnAVeGu4BsEKF01M0TRlQV7PrLO_RtAMm5MNo-3IaAuMtpnRFqg_IHf3lAh4nR_0m-92sh8LpNCdckrLqIKTTas97jLGKJysGlmQVygbi4oCAghuqi6AH0aAK3sMaVnG4ofujhaUYE5h2TxL187aaCEvrSG2BVdekBf7ZnwTj6h1sd-NNKKC6bApyKNRGfZDkgiJVEtdELNQk8WYly3d-Y8M9g0BIIy7VE_-e4BPyS2R9VizUh-Rw-1mF59B5LT1z7M5_AVEKBOw priority: 102 providerName: Scholars Portal |
| Title | Effect of alirocumab on cataracts in patients with acute coronary syndromes |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37328736 https://www.proquest.com/docview/2827054284/abstract/ https://search.proquest.com/docview/2827258809 https://pubmed.ncbi.nlm.nih.gov/PMC10276414 https://doaj.org/article/301a764a463e4ca39d6b0073ee2a3593 |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBZJCqWX0nfdposKhR6KsrIkS_IxGxJCy4YQGlh6EZIspwtdO-zj0H_fkWxvY3rrxQdrjK15aGakmc8IffKFVFT5mthClkRoJ4nltSDKcUbLuvDOxebk-ZW8vBVfF8XiAMmhFyYV7Xu3PGl-rU6a5c9UW3m_8tOhTmx6PT8Dp6ikyMX0EB0qzoccvU-z4tnW0B6j5XQDK7COhbacxPCfkfhzGB4xalTCZf7rjRJo_79L8wPfNK6bfOCILp6hp30EiU-7L32ODkLzAj2e92fkL9G3DpAYtzWGGBv8025lHW4bHHdqYk_UBi8b3OOpbnDciMXW77YB-4hmYNe_8QBjsHmFbi_Ov59dkv6XCQSYLrZEM-cK6j3VVW1FbSFAoi6vIErzuXe1E7yqysBYTStaOKlcoWwePGWuUlYHzV-jo6ZtwluEnfS-DrmFfIQKTytNJUiP2aBDHXSZZ-jLwDpz3yFjmJRRaGk6nhvguUk8N0A9i9zdU0ZU63SjXd-ZXrYGSOF1wgrJg_CWl5V08SgxBGZ5UfIMfY6yMdH2QADe9i0E8MERxcqcQu6VAPfhdccjSrAZPx4epGt6m90YSD4VBLDgrzP0cT8cn4x1aE1odx0NK2DNKzP0plOG_ZQGncqQHqnJaM7jEVDwhOg9KPS7_3_0PXrCko5LkstjdLRd78IHiJe2bgJGslAT9Gh2fnV9M0m7DnCdCw3Xm9mPSTKfPxrGGUs |
| link.rule.ids | 230,315,733,786,790,870,891,2115,12083,21416,24346,27957,27958,31754,31755,33779,33780,43345,43840,53827,53829 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZgKwEXxJtAASMhcUBWHdtxnBNqUauFdlcItVJvlu040ANJ2ewe-PfMJN6lERLXeCLb8x4_PhPyLhS65GVomCt0xZTxmjnZKFZ6KXjVFMF7vJy8WOr5hfpyWVymBbc-Havc-sTBUdddwDXyAygNSkgvwJt-vP7F8NUo3F1NT2jcJntKQqkyI3tHx8uv33YlF-5zba_KGH3Qgzc2eOhWMiwFBMsn4WhA7f_XN98ITtODkzci0ckDcj-lkPRwlPlDciu2j8idRdokf0xOR0Ri2jUUkmwIUJufztOupbhUg5eienrV0gSo2lNciaUubNaRBoQzcKvfdItj0D8hFyfH55_mLL2ZwIDras2M8L7gIXBTN041DjIk7vMa0rSQB994Jeu6ikI0vOaF16UvSpfHwIWvS2eikU_JrO3a-JxQr0NoYu6gIOEq8NpwDeITLprYRFPlGfmwZZ29HqEx7FBSGG1HRltgtB0YbYH6CLm7o0RY6-FDt_puk5VYIIXulFNaRhWcrGrtcS8xRuFkUcmMvEfZWDQ-EEBw6Q4BDBhhrOwhFF8D4j50tz-hBKMJ0-atdG0y2t7-VbGMvN014594EK2N3WakEQU4vSojz0Zl2E1JIvBRKXVGzERNJnOetrRXPwZIb0jzYN65evH_cb0hd-fnizN79nl5-pLcE4Mia5brfTJbrzbxFSRIa_86WcEfwxkO6w |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSBUX3pRAASMhcUDZOLbjOMdSWBXKVj1QqRIHy3ZsWMEmq032AL-ecR5LA7de47ESZ972zGeEXttM5CS3PtaZKGIujYg18zzODaOk8Jk1JjQnL87EyQX_dJldDlWVzVBWWVmznFU_V7Nq-b2rrVyvbDLWiSXni2NwirngKU_WpU9uolugtLQYM_Uh2QonXGOTjBRJA3ZYhnJbFockgMbhihgWkGryDp35r0_qoPv_N9BXPNS0evKKO5rfRV_HhfRVKD9m29bM7O9_MB6vt9J76M4QpeKjnuY-uuGqB2h_MZzDP0SnPegxrj2GOB584HalDa4rHHaDQt9Vg5cVHjBbGxw2e7G229ZhGxAT9OYXHqESmkfoYv7hy_FJPFzLEANjeRtLakxGrCWy9Jp7DUEYMWkJkaBNrfGGs7IsHKWelCQzIjdZrlNnCTVlrqWT7DHaq-rKPUHYCGu9SzXkPIRbUkoiQEKodtJ5J4s0Qm9Hxqh1j76huqxFCtVzVAFHVcdRBdTvAu92lAE5u3tQb76p4a8qIIXXcc0Fc9xqVpTChONK56hmWcEi9CZwXgX9BvZaPbQpwAcHpCx1BPldB-oPrzucUIJe2unwKDtqsAuNggQ3hyAZYoIIvdoNh5mh1q1y9banoRnY1SJCB72o7ZY0SmyE5EQIJ2uejoBodajhoyg9vf7Ul2j__P1cff54dvoM3aadMok4FYdor91s3XMIz1rzotPDP5jDOI4 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+alirocumab+on+cataracts+in+patients+with+acute+coronary+syndromes&rft.jtitle=BMC+ophthalmology&rft.au=Suc%2C+Gaspard&rft.au=Schwartz%2C+Gregory+G&rft.au=Goodman%2C+Shaun+G&rft.au=Jukema%2C+J.+Wouter&rft.date=2023-06-16&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2415&rft.eissn=1471-2415&rft.volume=23&rft.issue=1&rft_id=info:doi/10.1186%2Fs12886-023-03012-1&rft.externalDocID=A753260071 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2415&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2415&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2415&client=summon |